2017-10-11 19:20:44 UTC

Duration of Hepatitis C Virus Therapy

Oct. 11, 2017

Shorter duration therapy reduces treatment costs and may also improve adherence. How short can therapy be and who would qualify?

Guidelines for the treatment of chronic hepatitis C virus (HCV) do not encourage treatment for less than 12 weeks. Benjamin Emmanuel, MPH, Eleanor M. Wilson, MD, and Shyam Kottilil, MD, PhD, explain in AGA Perspectives that there is mounting evidence that many patients can achieve sustained virologic response with only eight weeks of treatment. The shorter duration therapy substantially reduces treatment costs and may also improve adherence as adherence tends to decrease as therapy duration increases. 

The authors recommend further exploration into shorter HCV therapy in target populations to address some of the issues that may arise, such as optimal retreatment strategies and the emergence of resistance-associated variants. 

Read the full article in AGA Perspectives.

More on Hepatitis C

Payer and Provider Workshops in HCV and HIV (Seattle, WA)

Nov. 14, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free dinner program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management. Identify approaches for better communication and efficient navigation of managed care requirements, and ways to leverage resources that can improve HCV and HIV care.

Payer and Provider Workshops in HCV and HIV (Indianapolis, IN)

Nov. 8, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free dinner program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management. Identify approaches for better communication and efficient navigation of managed care requirements, and ways to leverage resources that can improve HCV and HIV care.

Payer and Provider Workshops in HCV and HIV (Tampa, FL)

Oct. 24, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free dinner program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management. Identify approaches for better communication and efficient navigation of managed care requirements, and ways to leverage resources that can improve HCV and HIV care.